Asset Details
Do you wish to reserve the book?
Outcomes and Complications After LUMiC ® Endoprosthetic Reconstruction of Periacetabular Defects-A Retrospective Cohort Analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Outcomes and Complications After LUMiC ® Endoprosthetic Reconstruction of Periacetabular Defects-A Retrospective Cohort Analysis
Do you wish to request the book?
Outcomes and Complications After LUMiC ® Endoprosthetic Reconstruction of Periacetabular Defects-A Retrospective Cohort Analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Outcomes and Complications After LUMiC ® Endoprosthetic Reconstruction of Periacetabular Defects-A Retrospective Cohort Analysis
2026
Overview
(1) Background: The reconstruction of periacetabular defects after tumor resection remains one of the most challenging procedures in orthopaedic oncology. The modular LUMiC
system was designed to improve fixation stability and reduce implant-related complications compared with earlier hemipelvic prostheses. We investigated patient and implant survival after LUMiC
reconstruction, complication types and functional outcomes. (2) Methods: Eighteen patients (8 men, 10 women; mean age 58.9 years) underwent LUMiC
endoprosthetic reconstruction between 2011 and 2025. Kaplan-Meier analysis was used to estimate patient and implant survival. Complications were categorized according to Henderson. Functional results were evaluated at follow-up using MSTS and TESS. (3) Results: Mean follow-up was 35.52 months (SD 36.89). Overall implant survival was 72.2%. Instability (27.8%) and infection (16.7%) were the leading complications. Two-thirds of patients required at least one revision (mean 3.1 revisions per case). Metastatic disease reduced patient survival (
= 0.012) but did not affect implant longevity (
= 0.31). Functional outcomes were available for only 3 of 18 patients and should therefore be regarded as exploratory. Mean MSTS was 58.9% (SD 21.43) and mean TESS was 73.4% (SD 6.836). (4) Conclusions: Despite high revision rates, the LUMiC
prosthesis provides durable fixation. Early revision does not appear to compromise implant survival. However, the small and heterogeneous cohort represents a limiting factor of this study.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.